Skyclarys approved: HSE to fund Friedreich’s ataxia drug for Irish patients
Decision confirmed ending long-running campaign The HSE’s senior management team said it will reimburse the treatment, which is manufactured by US biotechnology company Biogen and costs €288,000 per patient per year. This comes after the HSE approved funding for Skyclarys, the drug used to treat Friedreich’s ataxia. The decision was confirmed on Tuesday, ending a […]
1 month ago
Skyclarys: Campaigners march in Dublin ahead of crunch HSE decision
What the Skyclarys decision turns heads Campaigners and patients marched through Dublin city centre on Sunday in a final push to have Skyclarys, a drug used to treat Friedreich’s Ataxia, approved for reimbursement by the HSE. The demonstration gathered at the Garden of Remembrance and made its way to Custom House Quay, three days before […]
1 month ago
Skyclarys: HSE to reconsider Friedreich’s Ataxia drug funding
When will a decision on Skyclarys be made? The HSE Drugs Group meets on Tuesday to reconsider whether to fund Skyclarys, the first treatment shown to slow the progression of Friedreich’s Ataxia. Around 200 people in Ireland live with the rare neurological disease and have campaigned for the drug to be made available on the […]
2 months ago